Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
Paton, Nicholas I, Musaazi, Joseph, Kityo, Cissy, Walimbwa, Stephen, Hoppe, Anne, Balyegisawa, Apolo, Asienzo, Jesca, Kaimal, Arvind, Mirembe, Grace, Lugemwa, Abbas, Ategeka, Gilbert, Borok, Margaret, Mugerwa, Henry, Siika, Abraham, Odongpiny, Eva Laker A, Castelnuovo, Barbara, Kiragga, Agnes, Kambugu, Andrew
Published in The lancet HIV (01.06.2022)
Published in The lancet HIV (01.06.2022)
Get more information
Journal Article